The stimulation of FLT3 signaling caused by c-Cbl mutant protein results in the constitutive activation of the AKT pathway (Figure 3) (Table 2), suggesting that FLT3 kinase is a potential therapeutic target for the treatment of c-Cbl mediated leukemia (Rathinam et al., 2010; Taylor et al., 2015). This evidence concerns the gene CBL and leukemia.